U.S. markets close in 3 hours 27 minutes
  • S&P 500

    4,455.10
    +59.46 (+1.35%)
     
  • Dow 30

    34,812.31
    +553.99 (+1.62%)
     
  • Nasdaq

    15,040.62
    +143.78 (+0.97%)
     
  • Russell 2000

    2,252.38
    +33.82 (+1.52%)
     
  • Crude Oil

    73.16
    +0.93 (+1.29%)
     
  • Gold

    1,750.90
    -27.90 (-1.57%)
     
  • Silver

    22.69
    -0.21 (-0.93%)
     
  • EUR/USD

    1.1745
    +0.0049 (+0.42%)
     
  • 10-Yr Bond

    1.4060
    +0.0700 (+5.24%)
     
  • GBP/USD

    1.3749
    +0.0129 (+0.95%)
     
  • USD/JPY

    110.1410
    +0.3630 (+0.33%)
     
  • BTC-USD

    43,817.02
    +638.91 (+1.48%)
     
  • CMC Crypto 200

    1,100.07
    -8.85 (-0.80%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Gilead's Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Gilead Sciences Inc's (NASDAQ: GILD) unit Kite Pharma has announced top-line results from the primary analysis of ZUMA-7 of Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line relapsed or refractory large B-cell lymphoma (LBCL).

  • Yescarta boosted event-free survival (EFS) over a standard of care regimen of physicians’-choice therapy followed by high-dose chemo plus a stem cell transplant.

  • At a two-year check-in, patients dosed with Yescarta posted a 60% relative increase in EFS over the standard of care.

  • The study also hit its secondary objective response rate endpoint, but overall survival data were still too immature to judge, Kite said.

  • The safety results from the study, which enrolled 359 patients across 77 treatment centers, were consistent with prior trials.

  • 6% of patients experienced grade 3 or higher cytokine release syndrome.

  • Kite plans to submit the data for regulatory approval in the US and EU later this year and present updated data at an upcoming medical meeting.

  • Price Action: GILD shares are up 0.87% at $68.47 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.